Intervention Protocol

Mycophenolate mofetil for liver-transplanted patients

  1. Katja Großmann1,*,
  2. Gero Langer1,
  3. Susanne Saal2,
  4. Dirk Grothues3,
  5. Andreas Wienke4

Editorial Group: Cochrane Hepato-Biliary Group

Published Online: 8 OCT 2008

DOI: 10.1002/14651858.CD007446


How to Cite

Großmann K, Langer G, Saal S, Grothues D, Wienke A. Mycophenolate mofetil for liver-transplanted patients (Protocol). Cochrane Database of Systematic Reviews 2008, Issue 4. Art. No.: CD007446. DOI: 10.1002/14651858.CD007446.

Author Information

  1. 1

    Martin Luther University Halle-Wittenberg, Institute for Health and Nursing Science, German Center for Evidence-based Nursing, Halle/Saale, Germany

  2. 2

    German Center for Evidence-based Nursing, Martin Luther University Halle-Wittenberg, Institute for Health and Nursing Science, Halle/Saale, Germany

  3. 3

    University Hospital Regensburg, Klinik und Poliklinik für Kinder- und Jugendmedizin, Regensburg, Germany

  4. 4

    Martin Luther University Halle-Wittenberg, Institute of Medical Epidemiology, Biostatistics and Informatics, Halle (Saale), Germany

*Katja Großmann, Institute for Health and Nursing Science, German Center for Evidence-based Nursing, Martin Luther University Halle-Wittenberg, Magdeburger Strasse 8, Halle/Saale, 06097, Germany. grossmann.katja@gmx.net.

Publication History

  1. Publication Status: New
  2. Published Online: 8 OCT 2008

SEARCH

 

Abstract

  1. Top of page
  2. Abstract

This is the protocol for a review and there is no abstract. The objectives are as follows:

To assess benefits and harms of mycophenolate mofetil and enteric-coated mycophenolate sodium as immunosuppressive agents for liver-transplanted patients. To assess separately usefulness for achieving current (or improved) targets in anti-rejection therapy and reducing calcineurin inhibitor side-effects of mycophenolate mofetil and enteric-coated mycophenolate sodium as immunosuppressive agents for liver-transplanted patients.